Lynparza® (olaparib) for ovarian and prostate cancer treatment

What Lynparza® Is and How It Works

Lynparza (olaparib) is a poly(ADP-ribose) polymerase (PARP) inhibitor used for selected ovarian, fallopian tube, primary peritoneal, breast, pancreatic, and metastatic castration-resistant prostate cancers with certain BRCA or homologous recombination repair (HRR) gene changes. Tablets are taken by mouth, usually twice daily. Many patients compare lynparza price across pharmacies because therapy is chronic and costs add up over time.

YouDrugstore is a licensed Canadian pharmacy based in Manitoba, where licensed pharmacists review prescriptions before dispensing; we offer brand and generic medicines at Canadian prices, plus OTC health products, with online and phone ordering and customer-service chat during posted hours.

Olaparib blocks PARP enzymes that help repair damaged DNA in cancer cells. When repair is blocked in tumors with BRCA or HRR defects, cancer cells accumulate damage and die. In ovarian cancer, Lynparza can be used as maintenance after response to platinum chemotherapy, including first-line maintenance in appropriate patients. In prostate cancer, it is used for metastatic castration-resistant disease with qualifying HRR alterations, sometimes with abiraterone and prednisone. It may also be used in selected HER2-negative, germline BRCA-mutated metastatic breast cancer and certain pancreatic cancers.

We source through licensed, vetted partner pharmacies worldwide to supply authentic brand medicines with a broad selection at budget-friendly prices.

Dosage and Usage

• Standard tablet dose: 300 mg by mouth twice daily (total 600 mg/day), taken consistently each day.
• Tablets may be taken with or without food; maintain a consistent pattern if possible.
• Swallow tablets whole. Do not crush, chew, or split.
• Avoid grapefruit, Seville oranges, and starfruit, which can increase olaparib levels.
• Avoid strong CYP3A inhibitors (e.g., itraconazole) or inducers (e.g., rifampin). If unavoidable, dose changes are often required under prescriber guidance.
• Renal impairment may require dose reductions. Severe hepatic impairment lacks robust data.
• Missed dose: skip and take the next dose at the regular time. Do not double doses.
• Report signs of infection or unusual bleeding; therapy may be held for low blood counts.

• Storage: keep tablets at 20–25°C (68–77°F); short excursions 15–30°C (59–86°F) are acceptable.
• Store in the original bottle with the desiccant to protect from moisture.
• Keep out of reach of children and pets.
• Travel: carry in original labeled container in carry-on luggage.
• Avoid leaving the bottle in hot cars or direct sunlight.
• If a trip spans multiple weeks, bring an extra few days of tablets in case of delays.
• Do not repack into pill organizers in humid environments.

Benefits and Savings

Lynparza can prolong progression-free survival in ovarian cancer maintenance and improve outcomes in appropriate metastatic prostate cancer. Tablets are convenient and taken at home, without IV visits. Dosing is steady, and most patients can maintain daily routines with supportive care for side effects.

Buying from Canada can lower costs substantially. Many patients see 60–80% savings compared with typical US prices. If tracking lynparza cost per month, consider multi-month supplies and bulk promotions, which may further reduce per-month expense.

For potential extra savings, check our lynparza coupon options when available.

Side Effects and Safety

• Very common: nausea, fatigue, anemia, decreased appetite, vomiting.
• Common: diarrhea, constipation, headache, dizziness, dysgeusia (taste changes).
• Common labs: low white blood cells or platelets; increased creatinine.
• Other reported: cough, shortness of breath, abdominal pain, arthralgia.

Serious risks are uncommon but include myelodysplastic syndrome/acute myeloid leukemia, pneumonitis/interstitial lung disease, and venous thromboembolism (notably when combined with abiraterone). Therapy is not recommended during pregnancy or breastfeeding. Strong CYP3A inhibitors or inducers can raise or lower olaparib levels and may require adjustments. Regular blood counts are standard during treatment.

Onset Time

Response timelines vary by cancer type and prior therapy. Nausea and fatigue often emerge in the first 1–3 weeks and can be managed. In ovarian cancer maintenance, markers such as CA-125 may trend lower within 1–3 months. Imaging assessments are typically scheduled every few months. In metastatic prostate cancer, PSA declines can appear within 4–8 weeks when used with abiraterone, with imaging responses evaluated over several months. Hematologic effects often stabilize after the first 8–12 weeks as doses are optimized.

Compare With Alternatives

Niraparib (Zejula) is another oral PARP inhibitor used for ovarian cancer maintenance. It offers once-daily dosing but can cause thrombocytopenia, especially early, which may require dose changes. Choice between olaparib and niraparib depends on mutation profile, prior treatments, and tolerability considerations.

Rucaparib (Rubraca) is a PARP inhibitor indicated in selected ovarian settings and previously in prostate cancer. Some uses have evolved with new data and regulatory updates. Differences across PARP inhibitors include dosing schedules, specific indications, and side-effect profiles; genomic testing guides selection.

Talazoparib (Talzenna) is another PARP inhibitor used in certain breast cancer settings and, in combination strategies, in prostate cancer. It may cause notable anemia and requires close monitoring. Discuss comparative efficacy and toxicity within the context of the tumor genotype and prior therapy.

For other tumor types and pathways, targeted agents may be used. For example, HER2-directed therapy such as Tukysa® may be used in HER2-positive metastatic breast cancer. Endocrine therapy such as Anastrozole is used for hormone receptor-positive breast cancer and is not interchangeable with PARP inhibition.

Combination Therapy

• Metastatic castration-resistant prostate cancer: olaparib may be combined with abiraterone and prednisone alongside ongoing androgen-deprivation therapy.
• Ovarian cancer: first-line maintenance may include olaparib with bevacizumab in eligible patients.
• Concurrent strong CYP3A inhibitors/inducers: dose adjustments or alternative agents are often needed to manage interactions.
• Hematologic toxicities: treatment interruptions or dose reductions may be used to manage anemia or neutropenia.
• Anticoagulation: assess clot risk, particularly if combining with abiraterone, and monitor for symptoms of thrombosis.

Patient Suitability and Cost-Saving Tips

Good candidates often include adults with BRCA-mutated or HRR-altered tumors in approved settings: maintenance after platinum response in ovarian cancer and specific metastatic prostate cancer indications. Eligibility also depends on prior therapies, overall health, and current lab values. Genetic testing and evidence of response to platinum help guide use in ovarian cancer.

Lynparza is generally avoided during pregnancy and breastfeeding. It may not be suitable with severe kidney or liver impairment. Avoid strong CYP3A inhibitors or inducers when possible. Vaccinations with live agents are typically deferred during active therapy. Always keep a current medication list to review interactions.

To manage budget, consider multi-month supplies when appropriate, which can lower per-month costs. Reorder reminders help prevent gaps in therapy. Tracking lynparza prostate cancer cost over time can support planning during long-term treatment. Discuss financial assistance and timing of refills to minimize shipping frequency.

Authoritative Sources

AstraZeneca Lynparza US Prescribing Information and Medication Guide

Health Canada Drug Product Database: Lynparza (olaparib)

FDA Label for Lynparza (olaparib) tablets

Order Lynparza® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This material is educational and does not replace advice from your healthcare professional. Always consult your prescriber or pharmacist about your specific treatment.